Additionally, the combination of fruquintinib and PD-1/PD-L1 inhibitors showed great efficacy for patients with MSS-metastatic CRC who failed standard treatment in some retrospective studies and phase II trials, with an ORR, median PFS, and median OS ranging from 7.1% to 21.05%, 5.4 to 9.6 months, and 11.1 to 13.7 months, respectively (18, 23, 24, 32). This evidence concerns the gene CD274 and colorectal carcinoma.